CyPath® Lung Test Demonstrates Clinical Utility in New Case Study

summarizeSummary

bioAffinity Technologies released a clinical case study demonstrating the real-world utility of its CyPath® Lung noninvasive diagnostic test in managing high-risk lung cancer patients.

check_boxKey Events

• Clinical Case Study Released

  The company issued a press release detailing a new clinical case study for its CyPath® Lung noninvasive diagnostic test.

• Demonstrates Clinical Utility

  The case study showed CyPath® Lung supported clinical decision-making for a high-risk patient with multiple pulmonary nodules, providing confidence for continued surveillance rather than immediate invasive procedures.

• Reduces Patient Anxiety

  The negative CyPath® Lung result helped reassure both the physician and patient, aligning with Lung-RADS 3 recommendations for a six-month CT surveillance schedule.

• Reinforces Product Value

  This validation highlights the test's 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules, supporting noninvasive management of indeterminate pulmonary nodules.

auto_awesomeAnalysis

bioAffinity Technologies announced a new clinical case study validating its CyPath® Lung diagnostic test. The study highlights the test's ability to support clinical decision-making for high-risk patients with pulmonary nodules, potentially reducing anxiety and unnecessary invasive procedures. This positive clinical validation reinforces the product's value proposition and builds on recent positive developments, including increased revenue for CyPath® Lung and new expert appointments.